Key result
Higher suPAR levels linked to depressive symptoms in schizophrenia, specifically in females.
Why the study?
Although low grade inflammation is increased in schizophrenia, inter-individual variation is large and associations with demographic, somatic, and psychiatric factors remain unclear.
Observational (n=187)
Increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting a sex-dependent aberrant immune activation.
Answers are grounded in this paper and cite their sources.
suPAR association with depressive symptoms appears sex-specific in schizophrenia; hypothesis-generating and requires longitudinal validation.
BACKGROUND: There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. METHOD: In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. RESULTS: Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. CONCLUSION: Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
No takes yet. Share an insight, caveat, or question.
Bigseth et al. (2021) conducted an observational in Schizophrenia (n=187). Soluble urokinase plasminogen activator receptor (suPAR) levels was evaluated on Association between depressive symptoms (CDSS sum score) and suPAR levels (beta 0.04, 95% CI 0.02 to 0.05, p=<0.001). Increased suPAR levels were associated with depressive symptoms in patients with schizophrenia, an association that was significant in females but not in males.
Synapse has enriched 10 related papers. Consider them for comparative context: